

Letter TJH-2015-0276.R1

Submitted: 25 July 2015

Accepted: 17 August 2015

Şinasi Özsoylu

sinasiozsoylu@hotmail.com

Megadose methylprednisolone (MDMP) for primary myelofibrosis (PMF)

Primer miyolofibrosisin megadose metilprednizolon ile tedavisi

I enjoyed reading Ayla et al.'s paper entitled "Ruxolimitib treatment in a patient with primary myelofibrosis resistant to conventional oral therapies and splenectomy: A case report" in the recent issue of the Journal (2015; 32:180-183).

In this well-studied case the authors included review of the literature without Turkish authors! The first case of PMF from this country was reported by us in 1957¹. More importantly long duration of remission with megadose methylprednisolone (MDMP; 30 mg/kg/day for 3 days, then 20 mg/kg/day for 4 days, subsequently 10, 5, 2 and 1 mg/kg dose each for a week given in 10-15 minutes i.v. initially later orally at once around 6 a.m.), almost a dozen patients with PMF published²⁻⁷ in international journals and including Turkish Journal of Hematology⁵⁻⁶.

The authors stated that "until recently, most treatments provided only palliative care with single treatment addressing all the complications and symptoms of the disorder." without taking into consideration of our results.

I believe that in review of the literature with Turkish authors' findings should also be taken into consideration to shed light on the treatment.

MDMP was also used with big success in the treatment of hematologic and non-hematologic disorders⁷. Most of the secondary myelofibrosis cases due to 25 (OH) cholecalciferol were also brought to attention by us⁸⁻⁹.

Since, I was very much disappointed with the literature review, once I thought I should change my name to Şimon to get some attention to my work in this country. But I saw Ali AYÇİÇEK's¹⁰ letter supporting our results in ITP treatment in the same issue of the Journal and I decided to move on the subjects before changing my name. I hope administration of MDMP to PMF and other hematologic disorders will be effective in international attention.

REFERENCES

1. Erman M, Ozsoylu S. Sur un cas d'anémie splénique erythromyeloïde de l'adulte. La Presse Medicale 1957; 65:1309-1310.
2. Ozsoylu S, Ruacan Ş. High dose intravenous corticosteroid treatment in childhood idiopathic myelofibrosis. Acta Haemat 1986; 5:49-51.
3. Ozsoylu S. High dose intravenous methylprednisolone for idiopathic myelofibrosis. Brit J Haemat 1988; 70:368-9.
4. Ozsoylu S, Ruacan Ş, Karaaslan Y, Dündar S. Megadose intravenous methylprednisolone in adult idiopathic myelofibrosis. Hematology Reviews 1991; 5(2):121-128.
5. Ozsoylu S. Treatment of primary myelofibrosis. Turk J Hematol 2009; 26:211-2.
6. Ozsoylu S. Mega-dose methylprednisolone (MDMP) for chronic idiopathic myelofibrosis. Turk J Hematology 2010; 27:314-315.
7. Ozsoylu S. High dose intravenous methylprednisolone (HIVMP) in haematologic disorders. Hematology Reviews 1990; 4(4):197-207.
8. Yetgin S, Ozsoylu S, Ruacan Ş, Tekinalp G, Çağlar M. Vitamin D deficiency rickets and myelofibrosis. Turk J Research in med Sciences 1987; 5:445-448.
9. Yetgin S, Ozsoylu S, et al. Vitamin D-deficiency rickets and myelofibrosis. J Pediatr 1989; 114:213-217.
10. Ayçiçek A. Platelet Levels of High- and Mega-Dose Methylprednisolone Treatment in Acute Immune Thrombocytopenia. Turk J Hematol 2015;32:186-187.